INSPIRED Symposium Part 4A: access to CAR T cell therapy in unique populations with B cell acute lymphoblastic leukemia
LE Winestone, D Bhojwani, S Ghorashian… - … and Cellular Therapy, 2024 - Elsevier
The approval of tisagenlecleucel (tisa-cel) for use in children with B cell acute lymphoblastic
leukemia (B-ALL) was based on the phase 2 ELIANA trial, a global registration study …
leukemia (B-ALL) was based on the phase 2 ELIANA trial, a global registration study …
The current socioeconomic and regulatory landscape of immune effector cell therapies
C Sainatham, D Yadav, A Dilli Babu… - Frontiers in …, 2024 - frontiersin.org
Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell
receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent …
receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent …
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
CD19–directed chimeric antigen receptor T-cell (CAR T) therapies, including axicabtagene
ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have …
ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have …
Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturing
N Bäckel, S Hort, T Kis, DF Nettleton… - Frontiers in Molecular …, 2023 - frontiersin.org
This paper discusses the challenges of producing CAR-T cells for cancer treatment and the
potential for Artificial Intelligence (AI) for its improvement. CAR-T cell therapy was approved …
potential for Artificial Intelligence (AI) for its improvement. CAR-T cell therapy was approved …
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T)
therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited …
therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited …
Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization …
Studies evaluating real-world outcomes and health care utilization for mantle cell lymphoma
are limited. We utilized national Medicare claims (2009–2019) to examine treatment …
are limited. We utilized national Medicare claims (2009–2019) to examine treatment …
Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T …
R Fyfe, O Anstis, K Kapadia, M Jordan, DO Sword… - BMJ open, 2024 - bmjopen.bmj.com
Objectives RE-TELL is a qualitative study, which aims to understand patient, support person,
clinician and coordinator experiences and perspectives of chimeric antigen receptor (CAR) …
clinician and coordinator experiences and perspectives of chimeric antigen receptor (CAR) …
Challenges in Global Access to CAR-T cells: an Asian Perspective
The use of cell therapy for clinical applications has seen a dramatic increase in recent years,
primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell …
primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell …
Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell …
C Cui, C Feng, N Rosenthal, SW Wade… - Leukemia & …, 2024 - Taylor & Francis
The efficacy of chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma
(LBCL) is well-established. This study, using the Premier PINC AI Healthcare Database …
(LBCL) is well-established. This study, using the Premier PINC AI Healthcare Database …
Ethics of genomic technologies in medicine
A Courtright-Lim, M Drago - Medicine, 2024 - Elsevier
This article explores the rapid shift of genomic technologies from biomedical research to
medical applications. This has led to the development of precision medicine, which can use …
medical applications. This has led to the development of precision medicine, which can use …